Roth Capital Trims PT on Ligand Pharma (LGND) to $150 Amid New Kyprolis Data (AMGN)

September 27, 2016 10:15 AM EDT
Get Alerts LGND Hot Sheet
Price: $93.51 -2.23%

Rating Summary:
    8 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade LGND Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Roth Capital lowers its price target on Buy-rated Ligand Pharmaceuticals (Nasdaq: LGND) from $151 to $150 following Kyprolis data out from Amgen (Nasdaq: AMGN) earlier today.

The firm commented, This is an unfortunate bump for Kyprolis. While Amgen has additional studies ongoing in the front-line setting, we believe that while product revenue will continue to grow, it could negatively impact the "slope" of the curve. Our adjusted revenue numbers for Kyprolis are below. With the negative data, Kyprolis remains in the negative perception zone for many, especially based on continuing commentary regarding the competitive landscape (Darzalex). We point to KOL feedback for the need of a proteasome inhibitor backbone and Kyprolis significantly outperformed Velcade in later treatment lines. Looking to our overall investment case for Ligand, we invoke our unchanged thesis of the company having a "buffered" downside based on negative partnered news based on 1) current core revenue streams, 2) new revenue streams just added and anticipated and 3) the sheer depth of the pipeline to spread overall risk out dramatically, in our belief.

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Roth Capital

Add Your Comment